Use of NSAIDs, COX‐2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population
Open Access
- 12 December 2002
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 47 (6), 595-602
- https://doi.org/10.1002/art.10796
Abstract
Objectives To identify determinants of cyclooxygenase 2 (COX-2) inhibitor versus nonsteroidal antiinflammatory drug (NSAIDs) or acetaminophen prescription in seniors; and to compare gastroprotective agent coprescriptions. Methods Administrative medical records were obtained from the government of Quebec health insurance agency. Three cohorts were formed based on prescriptions at study entry: COX-2 inhibitors, NSAIDs, or acetaminophen. Logistic regressions were used to adjust for potential confounders. Results We identified 42,267 patients taking COX-2 inhibitors, 8,235 taking NSAIDs, and 19,716 taking acetaminophen. Determinants of utilizing COX-2 inhibitors versus NSAIDs and versus acetaminophen, respectively, include: female gender (odds ratio [OR] 1.47; 95% confidence interval [95% CI] 1.39–1.55 and OR 1.17; 95% CI 1.12–1.22); musculoskeletal diseases (OR 1.87; 95% CI 1.76–2.00 and OR 2.20; 95% CI 2.10–2.31); and prior gastrointestinal hospitalization (OR 1.82; 95% CI 1.19–2.78 and OR 0.77; 95% CI 0.64–0.92). Gastroprotective agent coprescriptions were lower with COX-2 inhibitors than NSAIDs: OR 0.53; 95% CI 0.48–0.58. Conclusions COX-2 inhibitors were more commonly used than NSAIDs in patients with musculoskeletal diseases and those with prior gastrointestinal hospitalizations. Adjusted odds ratios showed a 47% decrease in gastroprotective agent coprescriptions with COX-2 inhibitors compared with NSAIDs.Keywords
This publication has 36 references indexed in Scilit:
- Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory DrugsEpidemiology, 2001
- Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritisClinical Therapeutics, 2001
- Cyclooxygenase-2–specific inhibitors: are they safe?American Journal Of Medicine, 2001
- Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in SwitzerlandPharmacoEconomics, 2001
- Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in OsteoarthritisPharmacoEconomics, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2Rheumatology, 1999
- Use of Acetaminophen and Nonsteroidal Anti-inflammatory Drugs: A Prospective Study and the Risk of Symptomatic Diverticular Disease in MenArchives of Family Medicine, 1998
- Guidelines for the management of rheumatoid arthritisArthritis & Rheumatism, 1996
- Guidelines for the medical management of osteoarthritisArthritis & Rheumatism, 1995